PHASEBIO PHARMACEUTICALS INC (PHAS) Fundamental Analysis & Valuation

NASDAQ:PHAS • US7172241090

Current stock price

0.0701 USD
-0.02 (-26.21%)
At close:
0.0533 USD
-0.02 (-23.97%)
After Hours:

This PHAS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. PHAS Profitability Analysis

1.1 Basic Checks

  • In the past year PHAS has reported negative net income.
  • PHAS had a negative operating cash flow in the past year.
PHAS Yearly Net Income VS EBIT VS OCF VS FCFPHAS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -20M -40M -60M -80M -100M

1.2 Ratios

Industry RankSector Rank
ROA -463.95%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PHAS Yearly ROA, ROE, ROICPHAS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 200 -200

1.3 Margins

Industry RankSector Rank
OM -12738.63%
PM (TTM) -12572.13%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PHAS Yearly Profit, Operating, Gross MarginsPHAS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. PHAS Health Analysis

2.1 Basic Checks

  • PHAS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for PHAS has been increased compared to 1 year ago.
  • PHAS has a better debt/assets ratio than last year.
PHAS Yearly Shares OutstandingPHAS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M
PHAS Yearly Total Debt VS Total AssetsPHAS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -42.67, we must say that PHAS is in the distress zone and has some risk of bankruptcy.
  • PHAS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -42.67
ROIC/WACCN/A
WACC8.15%
PHAS Yearly LT Debt VS Equity VS FCFPHAS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 50M -50M

2.3 Liquidity

  • PHAS has a Current Ratio of 0.47. This is a bad value and indicates that PHAS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • A Quick Ratio of 0.47 indicates that PHAS may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.47
Quick Ratio 0.47
PHAS Yearly Current Assets VS Current LiabilitesPHAS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. PHAS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 36.61% over the past year.
  • PHAS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -92.09%.
  • Measured over the past years, PHAS shows a very strong growth in Revenue. The Revenue has been growing by 152.85% on average per year.
EPS 1Y (TTM)36.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.33%
Revenue 1Y (TTM)-92.09%
Revenue growth 3Y152.85%
Revenue growth 5YN/A
Sales Q2Q%-97.99%

3.2 Future

  • PHAS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.15% yearly.
  • The Revenue is expected to grow by 59.56% on average over the next years. This is a very strong growth
EPS Next Y59.21%
EPS Next 2Y25.98%
EPS Next 3Y19.21%
EPS Next 5Y10.15%
Revenue Next Year-64.49%
Revenue Next 2Y-51.62%
Revenue Next 3Y19.06%
Revenue Next 5Y59.56%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
PHAS Yearly Revenue VS EstimatesPHAS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
PHAS Yearly EPS VS EstimatesPHAS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. PHAS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PHAS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PHAS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PHAS Price Earnings VS Forward Price EarningsPHAS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0
PHAS Per share dataPHAS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as PHAS's earnings are expected to grow with 19.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.98%
EPS Next 3Y19.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PHAS Dividend Analysis

5.1 Amount

  • PHAS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

PHAS Fundamentals: All Metrics, Ratios and Statistics

PHASEBIO PHARMACEUTICALS INC

NASDAQ:PHAS (11/2/2022, 8:00:01 PM)

After market: 0.0533 -0.02 (-23.97%)

0.0701

-0.02 (-26.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12
Earnings (Next)11-22
Inst Owners4.63%
Inst Owner Change0%
Ins Owners10.5%
Ins Owner Change0%
Market Cap3.50M
Revenue(TTM)818.00K
Net Income(TTM)-102.84M
Analysts45.71
Price Target1.02 (1355.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)29.53%
Min EPS beat(2)-7.01%
Max EPS beat(2)66.06%
EPS beat(4)1
Avg EPS beat(4)0.43%
Min EPS beat(4)-50.57%
Max EPS beat(4)66.06%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-85.31%
Min Revenue beat(2)-95.08%
Max Revenue beat(2)-75.53%
Revenue beat(4)0
Avg Revenue beat(4)-82.99%
Min Revenue beat(4)-95.08%
Max Revenue beat(4)-69.21%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.27
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 0
EPS(TTM)-2.13
EYN/A
EPS(NY)-1.25
Fwd EYN/A
FCF(TTM)-1.24
FCFYN/A
OCF(TTM)-1.19
OCFYN/A
SpS0.02
BVpS-2.35
TBVpS-2.35
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -463.95%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -12738.63%
PM (TTM) -12572.13%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 123.76%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.47
Quick Ratio 0.47
Altman-Z -42.67
F-Score2
WACC8.15%
ROIC/WACCN/A
Cap/Depr(3y)330.2%
Cap/Depr(5y)263.94%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.33%
EPS Next Y59.21%
EPS Next 2Y25.98%
EPS Next 3Y19.21%
EPS Next 5Y10.15%
Revenue 1Y (TTM)-92.09%
Revenue growth 3Y152.85%
Revenue growth 5YN/A
Sales Q2Q%-97.99%
Revenue Next Year-64.49%
Revenue Next 2Y-51.62%
Revenue Next 3Y19.06%
Revenue Next 5Y59.56%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-11.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11.05%
OCF growth 3YN/A
OCF growth 5YN/A

PHASEBIO PHARMACEUTICALS INC / PHAS Fundamental Analysis FAQ

What is the fundamental rating for PHAS stock?

ChartMill assigns a fundamental rating of 2 / 10 to PHAS.


What is the valuation status of PHASEBIO PHARMACEUTICALS INC (PHAS) stock?

ChartMill assigns a valuation rating of 2 / 10 to PHASEBIO PHARMACEUTICALS INC (PHAS). This can be considered as Overvalued.


How profitable is PHASEBIO PHARMACEUTICALS INC (PHAS) stock?

PHASEBIO PHARMACEUTICALS INC (PHAS) has a profitability rating of 0 / 10.